Vaccines pose a particular risk for long Covid, study finds

Advertisement

Supported by

In the first two years of the pandemic, the rate of long Covid fell particularly among vaccinated people, the researchers reported.

By Pam Belluck

A new large-scale study provides some of the most powerful evidence yet that vaccines risk causing long Covid.

Scientists looked at affected people in the United States during the first two years of the pandemic and found that the percentage of vaccinated people who developed long Covid was much lower than the percentage of unvaccinated people who did.

Medical experts have said in the past that vaccines can reduce the risk of long Covid, largely because they help prevent serious illness at the time of infection, and other people with serious infections are more likely to experience long-term symptoms. .

But many other people with mild infections also develop long Covid, and the study, published Wednesday in the New England Journal of Medicine, found that vaccination did not eliminate all risk of contracting the disease, which continues to affect other people. millions more people in the United States.

“There is a residual threat of long Covid among vaccinated people,” Dr. Clifford Rosen, a senior scientist at the MaineHealth Research Institute, who was not involved in the study, wrote in an accompanying editorial. For this reason, Dr. Rosen added, new cases of long Covid “could continue unabated. “

The study evaluated the medical records of millions of patients in the Department of Veterans Affairs health care system. This was approximately 450,000 more people who had Covid between March 1, 2020 and January 31, 2022, and about 4. 7 million more people who did not inflame this period.

We are recovering the content of the article.

Please allow javascript in your browser settings.

Thank you for your patience as we determine access. If you’re in player mode, log out and log in to your Times account or subscribe to the full Times.

Thank you for your patience while we determine access.

Already subscribed?  Sign in.

Do you want all the Times?  Subscribe.

Advertisement

Leave a Comment

Your email address will not be published. Required fields are marked *